AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10209702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg once daily)
Number of subjects: 632
Study 10209702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 632
Study 10209702 — intervention group
Group type: COMPARATOR
Intervention: Mizolastine (in PAR trial)
Number of subjects: 632
Study 10209702 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in PAR trial)
Number of subjects: 632
Study 7796237 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-extubation nasal continuous positive airway pressure (N-CPAP)
Number of subjects: 50
Study 7796237 — intervention group
Group type: COMPARATOR
Intervention: Post-extubation headbox
Number of subjects: 50
Study 2254723 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified conventional treatment (ICT, n = 44)
Number of subjects: 97
Study 2254723 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment (RT, n = 53)
Number of subjects: 97
Study 7410896 — intervention group
Group type: EXPERIMENTAL
Intervention: A/New Jersey subvirion vaccine
Number of subjects: 0
Study 7410896 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-virus vaccine
Number of subjects: 0
Study 7410896 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent subvirion vaccine
Number of subjects: 0
Study 7410896 — intervention group
Group type: EXPERIMENTAL
Intervention: Subvirion vaccines
Number of subjects: 0
Study 7410896 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural infection with A/USSR (H1N1)
Number of subjects: 0
Study 31739130 — intervention group
Group type: EXPERIMENTAL
Intervention: FROGS
Number of subjects: 228
Study 31739130 — intervention group
Group type: EXPERIMENTAL
Intervention: mini-FROGS
Number of subjects: 228
Study 31739130 — intervention group
Group type: COMPARATOR
Intervention: FROGS and mini-FROGS
Number of subjects: 228
Study 31138319 — intervention group
Group type: EXPERIMENTAL
Intervention: min(three Kruskal-Wallis [KW] test P values) > 0.30
Number of subjects: 0
Study 31138319 — intervention group
Group type: EXPERIMENTAL
Intervention: min(analysis of variance [ANOVA] P value) > 0.30
Number of subjects: 0
Study 31138319 — intervention group
Group type: EXPERIMENTAL
Intervention: min(nine possible t test P values) > 0.30
Number of subjects: 0
Study 31138319 — intervention group
Group type: EXPERIMENTAL
Intervention: min(Wilcoxon rank-sum [WRS] P values) > 0.30
Number of subjects: 0
Study 31138319 — intervention group
Group type: EXPERIMENTAL
Intervention: multivariate analysis of variance (MANOVA) P value > 0.30
Number of subjects: 0
Study 27161196 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoinsight® psychological enhancing method (art video shown before rehabilitation sessions for 15 days post-surgery and three times a week for 4 weeks)
Number of subjects: 110
Study 27161196 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video support, same rehabilitation protocol)
Number of subjects: 110
Study 26493989 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 291
Study 26493989 — intervention group
Group type: COMPARATOR
Intervention: No IPT (Control)
Number of subjects: 291
Study 23208460 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 mg)
Number of subjects: 110
Study 23208460 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (400 mg)
Number of subjects: 110
Study 20609098 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh muscle cross-sectional area (CSA)
Number of subjects: 49
Study 20609098 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular lipid
Number of subjects: 49
Study 20609098 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermuscular adipose tissue (IMAT)
Number of subjects: 49
Study 20609098 — intervention group
Group type: EXPERIMENTAL
Intervention: CSA
Number of subjects: 49
Study 18206407 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich gel (PRG) treatment
Number of subjects: 23
Study 18206407 — intervention group
Group type: COMPARATOR
Intervention: Control (no PRG treatment)
Number of subjects: 23
Study 16339924 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-receptor antagonist (graded doses)
Number of subjects: 25
Study 12571292 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte implantation
Number of subjects: 40
Study 12571292 — intervention group
Group type: COMPARATOR
Intervention: Osteochondral cylinder transplantation
Number of subjects: 40
Study 10952702 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 1000 IU/day with calcium and phosphorus supplemented breast milk
Number of subjects: 30
Study 10952702 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 500 IU/day with calcium and phosphorus supplemented breast milk
Number of subjects: 30
Study 10952702 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and phosphorus supplemented breast milk
Number of subjects: 30
Study 10952702 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and phosphorus unsupplemented breast milk
Number of subjects: 30
Study 10952702 — intervention group
Group type: COMPARATOR
Intervention: Preterm infants
Number of subjects: 30
Study 10952702 — intervention group
Group type: COMPARATOR
Intervention: Controls (children aged 2 years)
Number of subjects: 30
Study 10952702 — intervention group
Group type: COMPARATOR
Intervention: Controls (children aged 9-11 years)
Number of subjects: 30
Study 8614377 — intervention group
Group type: EXPERIMENTAL
Intervention: Study solution (25 microgram/ml of both amikacin and vancomycin added to the standard solution)
Number of subjects: 69
Study 8614377 — intervention group
Group type: COMPARATOR
Intervention: Standard solution (normal saline + 100 U/ml of heparin)
Number of subjects: 69
Study 1475987 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg oral dose of famotidine administered at 10:00 p.m.
Number of subjects: 38
Study 1475987 — intervention group
Group type: COMPARATOR
Intervention: 40 mg oral dose of famotidine administered at 6 p.m.
Number of subjects: 38
Study 3900079 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate 320 mg/ml
Number of subjects: 100
Study 3900079 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate 200 mg/ml
Number of subjects: 100
Study 30266466 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid/carboxymethylcellulose (HA/CMC) instillation
Number of subjects: 76
Study 30266466 — intervention group
Group type: COMPARATOR
Intervention: Control (no HA/CMC instillation)
Number of subjects: 76
Study 27161505 — intervention group
Group type: EXPERIMENTAL
Intervention: Taiwan Odd‐Even Number Sequencing Test (TOENST)
Number of subjects: 364
Study 27161505 — intervention group
Group type: COMPARATOR
Intervention: Conventional WM tests
Number of subjects: 364
Study 27157059 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 0
Study 27157059 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study 27157059 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 0
Study 25042993 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic resonance whole body vibration (SR-WBV) intervention
Number of subjects: 27
Study 25042993 — intervention group
Group type: COMPARATOR
Intervention: Sham group (SG)
Number of subjects: 27
Study 22698488 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg daily for 7 days
Number of subjects: 54
Study 22698488 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg daily for 7 days
Number of subjects: 54
Study 19887304 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 40 mg/m² on day 1, continuous infusion ifosfamide (IFO) 1700 mg/m² on days 1-3, mesna, every 28 days for 6-9 cycles
Number of subjects: 98
Study 19887304 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 98
Study 17823365 — intervention group
Group type: COMPARATOR
Intervention: Statin/ACEI combination treatment at standard doses (STD, ramipril 2.5/simvastatin 20 mg, or atorvastatin 10 mg)
Number of subjects: 22
Study 17823365 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin/ACEI combination treatment at high doses (HiDo, ramipril 10 mg, or enalapril 20 mg/simvastatin 80 mg, or atorvastatin 40 mg)
Number of subjects: 22
Study 17823365 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses (HiDo) treatment
Number of subjects: 22
Study 17823365 — intervention group
Group type: COMPARATOR
Intervention: Standard doses (STD) treatment
Number of subjects: 22
Study 17257158 — intervention group
Group type: EXPERIMENTAL
Intervention: NBM+PRP+GTR
Number of subjects: 30
Study 17257158 — intervention group
Group type: COMPARATOR
Intervention: NBM+GTR
Number of subjects: 30
Study 15629285 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy alone (group A)
Number of subjects: 68
Study 15629285 — intervention group
Group type: COMPARATOR
Intervention: Vitrectomy with scleral buckling (group B)
Number of subjects: 68
Study 11057354 — intervention group
Group type: EXPERIMENTAL
Intervention: Patanol (olopatadine hydrochloride ophthalmic solution 0.1%) with placebo tablet
Number of subjects: 29
Study 11057354 — intervention group
Group type: COMPARATOR
Intervention: Claritin (loratadine 10 mg) with placebo
Number of subjects: 29
Study 9483177 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaspan (PES)
Number of subjects: 12
Study 9483177 — intervention group
Group type: COMPARATOR
Intervention: Albumin
Number of subjects: 12
Study 8363164 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium, 5.1 g twice a day
Number of subjects: 118
Study 8363164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 8363164 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium
Number of subjects: 118
Study 3746280 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylalanine loading
Number of subjects: 13
Study 3746280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31551138 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil-propofol admixture (ADMIX)
Number of subjects: 40
Study 31551138 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil-atropine followed by propofol (ATRO)
Number of subjects: 40
Study 31551138 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 40
Study 29993221 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-modulator patch
Number of subjects: 140
Study 29993221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 29993221 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-market follow-up
Number of subjects: 140
Study 26822397 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrectomy followed by chemotherapy
Number of subjects: 175
Study 26822397 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 175
Study 23875987 — intervention group
Group type: EXPERIMENTAL
Intervention: WTQ-T advertisements (emotional, personal testimonies)
Number of subjects: 3002
Study 23875987 — intervention group
Group type: EXPERIMENTAL
Intervention: WTQ-G advertisements (graphic images)
Number of subjects: 3002
Study 23875987 — intervention group
Group type: EXPERIMENTAL
Intervention: WTQ-T + HTQ advertisements (combination)
Number of subjects: 3002
Study 23875987 — intervention group
Group type: EXPERIMENTAL
Intervention: HTQ advertisements (how-to-quit)
Number of subjects: 3002
Study 23875987 — intervention group
Group type: COMPARATOR
Intervention: No-ad condition (control)
Number of subjects: 3002
Study 22516909 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric carbohydrate (CHO) supplementation
Number of subjects: 11
Study 22516909 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-protein (CHO-Pro) supplementation
Number of subjects: 11
Study 19711036 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transfemoral TAVI
Number of subjects: 101
Study 17261389 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day death or nonfatal myocardial infarction (MI) for whites
Number of subjects: 7073
Study 17261389 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day death or nonfatal myocardial infarction (MI) for African-Americans
Number of subjects: 7073
Study 17261389 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day death or nonfatal myocardial infarction (MI) for Hispanics
Number of subjects: 7073
Study 17261389 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted odds ratio for African-American patients compared to white patients for 30-day death or MI
Number of subjects: 7073
Study 17261389 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of percutaneous coronary intervention
Number of subjects: 7073
Study 17261389 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of coronary artery bypass grafting
Number of subjects: 7073
Study 17261389 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequencies of hypertension
Number of subjects: 7073
Study 17261389 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month death or MI
Number of subjects: 7073
Study 15108107 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal epinephrine injection (1/10,000)
Number of subjects: 69
Study 15108107 — intervention group
Group type: COMPARATOR
Intervention: No injection (control group)
Number of subjects: 69
Study 11666122 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral TTFCA (60 mg tablets twice daily) for 4 weeks
Number of subjects: 50
Study 11666122 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 50
Study 9638718 — intervention group
Group type: EXPERIMENTAL
Intervention: Pall BC1B leucocyte-depleting filter for blood cardioplegia
Number of subjects: 40
Study 9638718 — intervention group
Group type: COMPARATOR
Intervention: No filter (control group)
Number of subjects: 40
Study 8013765 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (900 mg/daily)
Number of subjects: 31
Study 8013765 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (300 mg/daily)
Number of subjects: 31
Study 3057851 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (260 mg/day)
Number of subjects: 61
Study 3057851 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (52 mg/day)
Number of subjects: 61
Study 3057851 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem and Hydrochlorothiazide
Number of subjects: 61
Study 3057851 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 61
Study 31809358 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-way texting (2wT) intervention
Number of subjects: 722
Study 31809358 — intervention group
Group type: COMPARATOR
Intervention: Routine in-person visits (control)
Number of subjects: 722
Study 30634094 — intervention group
Group type: EXPERIMENTAL
Intervention: Single leg squat (painful leg group)
Number of subjects: 32
Study 30634094 — intervention group
Group type: COMPARATOR
Intervention: Single leg squat (dominant leg)
Number of subjects: 32
Study 30634094 — intervention group
Group type: COMPARATOR
Intervention: Single leg squat (non-dominant leg)
Number of subjects: 32
Study 30634094 — intervention group
Group type: COMPARATOR
Intervention: Running (all groups)
Number of subjects: 32
Study 30634094 — intervention group
Group type: EXPERIMENTAL
Intervention: Single leg squat (remaining groups)
Number of subjects: 32
Study 28865588 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular active toe movement
Number of subjects: 100
Study 28865588 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active toe movement)
Number of subjects: 100
Study 25803665 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor social contacts
Number of subjects: 5972
Study 25803665 — intervention group
Group type: EXPERIMENTAL
Intervention: High score of skills on seeking guidance and support, problem solving, seeking alternative rewards
Number of subjects: 5972
Study 25803665 — intervention group
Group type: EXPERIMENTAL
Intervention: High score of acceptance or resignation, emotional discharge, logical analysis
Number of subjects: 5972
Study 25803665 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance coping skills
Number of subjects: 5972
Study 25803665 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach coping skills
Number of subjects: 5972
Study 25803665 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network
Number of subjects: 5972
Study 23370314 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin with conatumumab (3 mg/kg)
Number of subjects: 172
Study 23370314 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin with conatumumab (15 mg/kg)
Number of subjects: 172
Study 23370314 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin with placebo
Number of subjects: 172
Study 23370314 — intervention group
Group type: EXPERIMENTAL
Intervention: Conatumumab treatment among V-allele carriers
Number of subjects: 172
Study 23370314 — intervention group
Group type: EXPERIMENTAL
Intervention: Conatumumab treatment among F-allele homozygotes
Number of subjects: 172
Study 21080021 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation synovectomy
Number of subjects: 97
Study 21080021 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid injection
Number of subjects: 97
Study 19548858 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesofensine 0.5 mg
Number of subjects: 0
Study 17092691 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER 6 mg
Number of subjects: 628
Study 17092691 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER 9 mg
Number of subjects: 628
Study 17092691 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER 12 mg
Number of subjects: 628
Study 17092691 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER (all doses)
Number of subjects: 628
Study 17092691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 628
Study 15523955 — intervention group
Group type: COMPARATOR
Intervention: PRK only
Number of subjects: 54
Study 15523955 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoothing technique after PRK
Number of subjects: 54
Study 15614647 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-week comprehensive coordinative training program
Number of subjects: 75
Study 15614647 — intervention group
Group type: COMPARATOR
Intervention: Age-matched healthy individuals
Number of subjects: 75
Study 11152164 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary/alternative medicine (CAM) therapies
Number of subjects: 0
Study 9186298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ingestion of 100 g glucose (OGTT)
Number of subjects: 11
Study 9186298 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-g protein meal
Number of subjects: 11
Study 9186298 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal glucagon levels
Number of subjects: 11
Study 9186298 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon response during OGTT
Number of subjects: 11
Study 8247951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 60 mg daily for 3 weeks
Number of subjects: 16
Study 8247951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 120 mg daily for 3 weeks
Number of subjects: 16
Study 8247951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin therapy
Number of subjects: 16
Study 3530444 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (ADR) 75 mg/m2 by iv bolus every 3 weeks
Number of subjects: 101
Study 3530444 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (ADR) 45 mg/m2 by iv bolus every 3 weeks and Mitomycin (MMC) 10 mg/m2 by iv bolus every 6 weeks
Number of subjects: 101
Study 31329288 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysfunctional coping strategies (measured by COPE 'avoidance strategies' scale)
Number of subjects: 72
Study 31329288 — intervention group
Group type: EXPERIMENTAL
Intervention: Major skin involvement (Cluster 1)
Number of subjects: 72
Study 31329288 — intervention group
Group type: EXPERIMENTAL
Intervention: Padua Skin-Related QoL questionnaire (PSRQ)
Number of subjects: 72
Study 30522508 — intervention group
Group type: EXPERIMENTAL
Intervention: Complaints to the ICUs
Number of subjects: 1029
Study 30522508 — intervention group
Group type: COMPARATOR
Intervention: Complaints to the general wards
Number of subjects: 1029
Study 27328578 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving simulator training (12 modules, with varying completion rates: 2-5 modules (n=8, 19%), 6-11 modules (n=7, 17%), all 12 modules (n=27, 64%))
Number of subjects: 215
Study 27328578 — intervention group
Group type: COMPARATOR
Intervention: Control group (no simulator training)
Number of subjects: 215
Study 24612915 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml/kg 30% lipid emulsions
Number of subjects: 60
Study 24612915 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution
Number of subjects: 60
Study 21632442 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic group
Number of subjects: 49
Study 21632442 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic group
Number of subjects: 49
Study 20697169 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline (250 μg) followed by oral terbutaline (20 mg/d) as maintenance
Number of subjects: 200
Study 20697169 — intervention group
Group type: COMPARATOR
Intervention: Intravenous salbutamol (0.1 mg) followed by oral salbutamol (24 mg/d) as maintenance
Number of subjects: 200
Study 18490472 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic double-bundle reconstruction
Number of subjects: 328
Study 18490472 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle reconstruction
Number of subjects: 328
Study 18490472 — intervention group
Group type: COMPARATOR
Intervention: Both procedures
Number of subjects: 328
Study 15990751 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with AVB
Number of subjects: 5251
Study 15990751 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with AVB and inferior MI
Number of subjects: 5251
Study 15990751 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with AVB and anterior MI
Number of subjects: 5251
Study 15990751 — intervention group
Group type: COMPARATOR
Intervention: Patients without AVB
Number of subjects: 5251
Study 12519083 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline (NaCl)
Number of subjects: 9
Study 12519083 — intervention group
Group type: EXPERIMENTAL
Intervention: Hartmann's solution
Number of subjects: 9